|
|
- Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer's disease
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled Preclinical development of new tetrahydrofur
- Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran deriva
- Anavex raises $1.575 million
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the company’s lead drug candidate
- Anavex to present at Alzheimer’s Association International Conference on Alzheimer's Disease
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh
- Bad Pharma
How drug companies mislead doctors and harm patients
Resource Type: Book
Published: 2012
Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply buried.
- Bad Pharma, Bad Journalism
Resource Type: Article
Published: 2012
‘The drugs don't work: a modern medical scandal’, from Ben Goldacre's new book, Bad Pharma presents a disturbing picture emerges of corporate drug abuse.
- Connexions
Volume 9, Number 1 - Spring 1984 - Energy - A Digest of Resources and Groups for Social Change
Resource Type: Serial Publication (Periodical)
Published: 1984
- Deception By Design
Pharmaceutical Promotion in the Third World
Resource Type: Book
Published: 1996
The authors discuss the workings of the pharmaceutical industry by exposing the unethical marketing practices, double standards and weak marketing codes.
- Herb/Drug Interactions: What You Don't Know CAN Hurt You
Sources News Release
Resource Type: Article
Published: 2010
Can combining prescription antidepressants and herbal medicine put your life at risk? Misconceptions abound when it comes to combining herbal medications and conventional drugs. Naturopathic doctors can help.
- NDMAC, Advancing Canadian Self-care
Media Profile in Sources
Resource Type: Organization
- Private Profits vs Public Policy
The Pharmaceutical Industry and the Canadian State
Resource Type: Book
Published: 2016
According to Joel Lexchin, "Given the central role that medicines play in keeping us healthy, it is essential that we understand the policy environment that governs drug development, from the initial basic research to the sale of the manufactured produces to the patients that use them."
- The Real Pushers
A Critical Analysis of the Canadian Drug Industry
Resource Type: Book
Published: 1984
A comprehensive analysis of the pharmaceutical drug industry in Canada.
|
AlterLinks
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.
|
|
|
|
